Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Memorial Cancer Institute's Best of ASCO® 2025